PORTFOLIO NEWS A2 Bio Identifying Solid Tumor Patients for Possible Inclusion in Phase 1 Studies Targeting CEA and Mesothelin Expected to Begin in 2023: Update at SITC 2022 November 7, 2022 Read More » NGM Bio Provides Business Highlights and Reports Third Quarter 2022 Financial Results November 3, 2022 Read More » NGM Bio Announces Presentation of Post-Hoc Analyses from CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) at The Retina Society Annual Scientific Meeting November 3, 2022 Read More » Nurix Therapeutics Reports Case Study of Patient with Aggressive Non-Hodgkin’s Lymphoma (NHL) Showing a Complete Clinical Response to NX-2127 at the 5th Annual Targeted Protein Degradation (TPD) Summit October 26, 2022 Read More » eFFECTOR Completes Enrollment in Second of Three Cohorts of Phase 1B Clinical Trial of Zotaifin for the Treatment of Covid-19 October 26, 2022 Read More » NGM Bio Announces Topline Results from the CATALINA Phase 2 Trial of NGM621 October 17, 2022 Read More » Surrozen Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt Agonist SZN-413 for People with Retinal Diseases October 6, 2022 Read More » Nurix Therapeutics Reports Third Quarter Fiscal 2022 Financial Results and Provides a Corporate Update October 6, 2022 Read More » eFFECTOR Appoints Mayank Gandhi, M.D., as Chief Business Officer September 26, 2022 Read More » Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of SZN-413 in Preclinical Models of Diabetic Retinopathy September 26, 2022 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Next »
A2 Bio Identifying Solid Tumor Patients for Possible Inclusion in Phase 1 Studies Targeting CEA and Mesothelin Expected to Begin in 2023: Update at SITC 2022 November 7, 2022 Read More »
NGM Bio Provides Business Highlights and Reports Third Quarter 2022 Financial Results November 3, 2022 Read More »
NGM Bio Announces Presentation of Post-Hoc Analyses from CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) at The Retina Society Annual Scientific Meeting November 3, 2022 Read More »
Nurix Therapeutics Reports Case Study of Patient with Aggressive Non-Hodgkin’s Lymphoma (NHL) Showing a Complete Clinical Response to NX-2127 at the 5th Annual Targeted Protein Degradation (TPD) Summit October 26, 2022 Read More »
eFFECTOR Completes Enrollment in Second of Three Cohorts of Phase 1B Clinical Trial of Zotaifin for the Treatment of Covid-19 October 26, 2022 Read More »
NGM Bio Announces Topline Results from the CATALINA Phase 2 Trial of NGM621 October 17, 2022 Read More »
Surrozen Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt Agonist SZN-413 for People with Retinal Diseases October 6, 2022 Read More »
Nurix Therapeutics Reports Third Quarter Fiscal 2022 Financial Results and Provides a Corporate Update October 6, 2022 Read More »
Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of SZN-413 in Preclinical Models of Diabetic Retinopathy September 26, 2022 Read More »